Titre : | Pharmacotherapy for smoking cessation: present and future (2011) |
Auteurs : | H. J. AUBIN ; L. KARILA ; M. REYNAUD |
Type de document : | Article : Périodique |
Dans : | Current Pharmaceutical Design (Vol.17, n°14, May 2011) |
Article en page(s) : | 1343-1350 |
Langues: | Anglais |
Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
Mots-clés : |
Thésaurus mots-clés ARRET DU TABAC ; TABAC ; ABSTINENCE ; SEVRAGE ; PHARMACOTHERAPIE ; SUBSTITUTS NICOTINIQUES ; BUPROPION ; VARENICLINE ; METHODE |
Résumé : | Tobacco dependence is a chronic disease that often requires repeated interventions and multiple attempts to quit. To date, three medications are FDA-approved for smoking cessation: nicotine replacement therapy, sustained-release bupropion, and varenicline. These treatments are effective across a broad range of populations, and are recommended for all smokers, including those with psychiatric or addictive comorbidity. Less is known however concerning the benefit-risk profile of these medications in pregnant women and adolescents. With these limitations in mind, clinicians should encourage and offer counseling and a prescription of pharmacotherapy to every patient willing to make a quit attempt. Despite the relative efficacy of first-line medications, many smokers relapse after one given quit attempt, and alternative pharmacotherapies are needed. Clonidine and nortriptyline have been proposed as second-line medications. In addition, this review indentifies a series of promising drugs that hopefully will be available to complete our current armory. |
Domaine : | Tabac / Tobacco / e-cigarette |
Sous-type de document : | Revue de la littérature / Literature review |
Refs biblio. : | 125 |
Affiliation : | Substance Abuse Treatment Center, Hopital Paul Brousse, Hopitaux Universitaires Paris-Sud, AP-HP, INSERM U669 University Paris-Sud, Villejuif, France |
Accueil